Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025Immunotherapy

Evaluating inebilizumab in the treatment of generalized myasthenia gravis

View Full Paper
Ask AI
Bookmark
Share

Authors

OCOlimpia Carbunar

Discussion

Loading...

Member takes

Implication

Review indicates clinical efficacy and favorable safety profile of inebilizumab in myasthenia gravis, suggesting its role in disease control and patient selection.

Key Points

  • Disease control observed with inebilizumab highlights its role in managing myasthenia gravis.
  • Clinical efficacy noted in a review suggests inebilizumab is effective in treating neuromuscular junction disorders.
  • Assessment of therapeutic options requires evaluating efficacy, safety profile, and comparative effectiveness of biologics.
  • Long-term outcomes and patient selection are critical for optimizing treatment in refractory myasthenia gravis.

Cite This Study

Olimpia Carbunar (2025) studied this question.

synapsesocial.com/papers/692b94261d383f2b2a378459https://doi.org/10.1080/1750743x.2025.2594349
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up2024 · 1,095 citations
  2. 2Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy2021 · 547 citations